Lysosomal adaptation: How cells respond to lysosomotropic compounds

• Shuyan Lu ,

  * E-mail: shuyan.lu@pfizer.com (SL); bart.jessen@pfizer.com (BAJ)

  Affiliation Drug Safety Research and Development, Pfizer Inc., San Diego, CA, United States of America

  ⨯
• Tae Sung,

  Affiliation Drug Safety Research and Development, Pfizer Inc., San Diego, CA, United States of America

  ⨯
• Nianwei Lin,

  Affiliation iXCells Biotechnologies, San Diego, CA, United States of America

  ⨯
• Robert T. Abraham,

  Affiliation Oncology Research Unit, Pfizer Inc., San Diego, CA, United States of America

  ⨯
• Bart A. Jessen

  * E-mail: shuyan.lu@pfizer.com (SL); bart.jessen@pfizer.com (BAJ)

  Affiliation Drug Safety Research and Development, Pfizer Inc., San Diego, CA, United States of America

  ⨯